Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2011/068851external-prioritypatent/WO2012055961A1/fr
Application filed by Amgen Res Munich GmbhfiledCriticalAmgen Res Munich Gmbh
Publication of TN2013000178A1publicationCriticalpatent/TN2013000178A1/fr
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
L'invention concerne des moyens et des méthodes de traitement du lymphome B diffus à grandes cellules (DLBCL). L'invention concerne en particulier l'administration d'un anticorps CDI 9 x CD3 bispécifique activant des lymphocytes T par l'intermédiaire de sa partie de liaison au CD3 et se liant de façon concomitante au CD! 9, notamment sur la surface des cellules du lymphome, par l'intermédiaire de sa partie de liaison au CD 19 (à savoir un activateur de lymphocytes T bispécifique, "Bi TE"), dans le traitement d'une masse tumorale de tissu lymphoréticulaire et/ou d'un lymphome extranodal causé par le DLBCL chez un patient.
TNP2013000178A2011-10-272013-04-24Moyens et methodes de traitement du lymphomeb diffus a grandes cellules
TN2013000178A1
(fr)
Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance
Pretreatment of glioblastoma with bortezomib potentiates natural killer cell cytotoxicity through TRAIL/DR5 mediated apoptosis and prolongs animal survival
RP105 engages phosphatidylinositol 3-kinase p110δ to facilitate the trafficking and secretion of cytokines in macrophages during mycobacterial infection
γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation